Target intelligence / Profile preview

Natural killer cell-mediated cytotoxicity pathway

Molecular classification
Other (signaling pathway, not a single molecule or receptor)
01

Overview

The **Natural killer cell-mediated cytotoxicity pathway** encompasses the recognition and destruction of stressed, infected, or transformed cells by NK cells, which are part of the innate immune system[1][2][3][4][5][6][7]. NK cells use diverse germline-encoded activating and inhibitory receptors to sense ligands on target cells. Upon activation, NK cells release cytotoxic granules containing perforin and granzymes, inducing apoptosis through membrane pore formation and caspase activation[1][3][4][5]. They also express death ligands (such as Fas ligand and TRAIL) that trigger extrinsic apoptotic pathways in target cells[1][3]. NK cells can mediate antibody-dependent cellular cytotoxicity (ADCC) by recognizing antibody-coated target cells via CD16[4][6]. These mechanisms are critical for immune surveillance against cancer and viral infections and are exploited by certain immunotherapies. However, the pathway is a functional property of NK cells, not a discrete molecular entity or single drug target.

Other names
NK cell cytotoxicity pathwayNK cell-mediated cytotoxic responseNK cytolytic pathwaynatural killer cytotoxicity
02

Mechanism of action

Activation of NK cell-mediated cytotoxicity via ADCC (e.g., antibody therapies engage CD16 on NK cells)[4][6]; Enhancement of death receptor-mediated apoptosis (experimental or investigational strategies)

03

Biological functions

Immune responseCell deathApoptosisClearance of senescent and abnormal cellsCancer immune surveillance
04

Disease associations

CancerInfectionInflammation (role in autoimmune diseases and aging)Neurodegenerative disease (e.g., clearance of senescent neurons in Parkinson's disease)
05

Safety considerations

Therapeutic challenge: limited persistence, exhaustion, and suppression of NK cells in tumor microenvironments[6]Possible off-target cytotoxicity and immunopathologyCytokine release syndrome (especially with engineered NK cell therapies)
06

Interacting drugs

rituximab

1 more in the full profile.

07

Biomarkers

CD107a (LAMP-1) degranulation marker[5]CD56 (NK cell marker in humans)[5]CD16 (FcγRIII, ADCC activation)[4][6]Perforin and granzyme B levels[1][3][5]

Beyond the preview

Go deeper on Natural killer cell-mediated cytotoxicity pathway.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Natural killer cell-mediated cytotoxicity pathway.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call